Ibrutinib,Tisagenlecleucel
abbvie,janssen,novartis
[' ibru', 'tarmac', 'tisa-cel', 'lymsm']
the tarmac trial combining ibrutinib w tisa-cel in mcl achieves its primary endpoint with an 80% complete response rate, w 2 pts continuing ibr due to mrd positivity but the rest having time-limited btki therapy. also included some btki-exposed pts #ash22 #lymsm 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer